Apellis Stock Analysis

APLS -  USA Stock  

USD 59.69  0.96  1.58%

The latest price spike of Apellis Pharmaceuticals could raise concerns from retail investors as the firm it trading at a share price of 59.69 on 675,400 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in July. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.0. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Apellis Pharmaceuticals partners.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Apellis Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Apellis Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Apellis stock analysis module also helps to analyze the Apellis Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Apellis Stock Analysis Notes

About 20.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.7. Apellis Pharmaceuticals had not issued any dividends in recent years. Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. For more info on Apellis Pharmaceuticals please contact Cedric Francois at 617 977 5700 or go to http://www.apellis.com.

Apellis Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Apellis Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Apellis Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Apellis Pharmaceuticals appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 250.65 M. Net Loss for the year was (359.71 M) with loss before overhead, payroll, taxes, and interest of (74.33 M).
Apellis Pharmaceuticals currently holds about 723.67 M in cash with (205.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.99.
Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.marketbeat.com: Apellis Pharmaceuticals, Inc. Director Sells 162,075.00 in Stock - MarketBeat

Apellis Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Apellis Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apellis Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of July 2021
Next Earnings Report1st of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Apellis Largest EPS Surprises

Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-04-30
2018-03-31-0.2734-0.43-0.156657 
2019-05-07
2019-03-31-0.6824-0.87-0.187627 
2018-07-31
2018-06-30-0.4182-0.61-0.191845 
View All Earnings Estimates

Apellis Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Apellis Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Apellis Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Apellis Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
1st of June 2021
Submission of Matters to a Vote of Security Holders
View
11th of March 2021
Entry into a Material Definitive Agreement
View
16th of February 2021
Unclassified Corporate Event
View
10th of February 2021
Unclassified Corporate Event
View
5th of February 2021
Unclassified Corporate Event
View
3rd of February 2021
Unclassified Corporate Event
View
26th of January 2021
Financial Statements and Exhibits. Other Events
View
7th of January 2021
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View

Apellis Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 5 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apellis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Apellis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Apellis Profitablity

Apellis Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Apellis Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Apellis Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Apellis Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Apellis Pharmaceuticals' profitability requires more research than a typical breakdown of Apellis Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (143.51) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (95.57) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.96.
Last ReportedProjected for 2021
Return on Average Assets(0.42) (0.45) 
Return on Average Equity(1.72) (1.86) 
Return on Invested Capital(0.50) (0.51) 
Return on Sales(1.12) (1.21) 

Management Efficiency

The entity has return on total asset (ROA) of (19.97) % which means that it has lost $19.97 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (231.58) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals management efficiency ratios could be used to measure how well apellis pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 06/17/2021, Return on Average Assets is likely to drop to -0.45. In addition to that, Return on Average Equity is likely to drop to -1.86. Apellis Pharmaceuticals Total Assets are relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Total Assets of 960.57 Million. As of 06/17/2021, Current Assets is likely to grow to about 989.6 M, while Return on Average Assets are likely to drop (0.45) .
Last ReportedProjected for 2021
Book Value per Share 2.72  3.24 
Enterprise Value over EBIT(14.00) (15.11) 
Enterprise Value over EBITDA(13.73) (14.82) 
Price to Book Value 21.18  24.21 
Tangible Assets Book Value per Share 12.78  11.14 
Enterprise Value4.3 B4.6 B
Tangible Asset Value960.6 MB

Technical Drivers

As of the 17th of June 2021, Apellis Pharmaceuticals shows the risk adjusted performance of 0.0765, and Mean Deviation of 2.67. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Apellis Pharmaceuticals, which can be compared to its rivals. Please confirm Apellis Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 59.69 per share. Given that Apellis Pharmaceuticals has jensen alpha of 0.3561, we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Apellis Pharmaceuticals Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Apellis Pharmaceuticals more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Apellis Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Timothy Sullivan over a week ago via Macroaxis 
Exercise or conversion by Timothy Sullivan of 880 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over two weeks ago via Macroaxis 
Acquisition or disposition of Apellis Pharmaceuticals securities by Dunlop A Sinclair
David Watson over two weeks ago via Macroaxis 
Exercise or conversion by David Watson of 489 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Pascal Deschatelets over three weeks ago via Macroaxis 
Sale by Pascal Deschatelets of 6250 shares of Apellis Pharmaceuticals
Dunlop A Sinclair over three weeks ago via Macroaxis 
Sale by Dunlop A Sinclair of 5773 shares of Apellis Pharmaceuticals
Delong Mark Jeffrey over three weeks ago via Macroaxis 
Exercise or conversion by Delong Mark Jeffrey of 2000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Federico Grossi over three weeks ago via Macroaxis 
Sale by Federico Grossi of 500 shares of Apellis Pharmaceuticals
Federico Grossi over a month ago via Macroaxis 
Sale by Federico Grossi of 600 shares of Apellis Pharmaceuticals
Nicole Perry over a month ago via Macroaxis 
Exercise or conversion by Nicole Perry of 1000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over a month ago via Macroaxis 
Exercise or conversion by Dunlop A Sinclair of 10000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
David Watson over a month ago via Macroaxis 
Exercise or conversion by David Watson of 489 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Alec Machiels over a month ago via Macroaxis 
Exercise or conversion by Alec Machiels of 2500 shares of Apellis Pharmaceuticals subject to Rule 16b-3

Apellis Pharmaceuticals Predictive Daily Indicators

Apellis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Apellis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Apellis Pharmaceuticals Forecast Models

Apellis Pharmaceuticals time-series forecasting models is one of many Apellis Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apellis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Apellis Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Apellis Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apellis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Apellis Pharmaceuticals. By using and applying Apellis Stock analysis, traders can create a robust methodology for identifying Apellis entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(1.12) (1.21) 
Gross Margin 0.90  0.89 
Profit Margin(1.24) (1.34) 
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Current Apellis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apellis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apellis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
73.92Buy12Odds
Apellis Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to Apellis conference calls.
Apellis Analyst Advice Details

Apellis Stock Analysis Indicators

Apellis Pharmaceuticals stock analysis indicators help investors evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Apellis Pharmaceuticals stock analysis, traders can identify Apellis Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio8.89
Fifty Two Week Low25.49
Shares Short Prior Month7.04M
Average Daily Volume Last 10 Day563.46k
Average Daily Volume In Three Month784.31k
Shares Percent Shares Out10.00%
Gross Margins-35.53%
Short Percent Of Float14.97%
Forward Price Earnings-10.28
Float Shares59.75M
Fifty Two Week High62.16
Enterprise Value To Ebitda-15.45
Fifty Day Average51.18
Two Hundred Day Average48.64
Enterprise Value To Revenue14.71
Please continue to Trending Equities. Note that the Apellis Pharmaceuticals information on this page should be used as a complementary analysis to other Apellis Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Apellis Pharmaceuticals Stock analysis

When running Apellis Pharmaceuticals stock analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' stock examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals stock's value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.